Halozyme Therapeutics, Inc.
NASDAQ: HALO
$39.91
+$0.31 (+0.8%)
Closing price September 21, 2023
Thursday's top analyst upgrades and downgrades included Airbnb, Alcon, Antero Midstream, Exact Sciences, GitLab, GlobalFoundries, Halozyme Therapeutics, Lumentum, Nektar Therapeutics, PayPal and...
4 months ago
Last Updated: 4 months ago
Monday’s top analyst upgrades and downgrades included Chipotle Mexican Grill, CRISPR, Hess Midstream, iMedia Brands, Kinder Morgan, Wendy’s and more.
2 years ago
Last Updated: 2 years ago
Monday's top analyst upgrades and downgrades included Foot Locker, Halozyme Therapeutics, Kimberley-Clark, Occidental Petroleum, Texas Roadhouse, Trip.com and Williams Companies.
2 years ago
Last Updated: 2 years ago
Thursday's top analyst upgrades and downgrades included Alphabet, Chevron, Citigroup, Facebook, Fastly, Paypal, Snap, Twitter and Under Armour.
2 years ago
Last Updated: 2 years ago
The top analyst upgrades, downgrades and initiations seen on Thursday include Aetna, Analog Devices, Lowe's, Merck, Pfizer, Plug Power, Qualcomm and Target.
5 years ago
Last Updated: 5 years ago
With 2017 nearing an end, it is important to consider just what has happened. 24/7 Wall St. has screened 50 stocks that have risen 100% or more (some far more) in 2017.
5 years ago
Last Updated: 2 years ago
Halozyme Therapeutics saw its shares make a handy gain early on Thursday after the firm announced that it licensed its Enhanze drug-delivery technology to Roche for exclusive development of an...
6 years ago
Last Updated: 3 years ago
As the markets are continuing to heat up, a few biopharma stocks made massive gains on Thursday. There is a very positive sentiment in the health care sector in anticipation of the new Trump...
6 years ago
Last Updated: 3 years ago
Over the past week, Halozyme Therapeutics and a couple of other biotech companies made impressive runs.
7 years ago
Last Updated: 3 years ago
These biotech companies stood out from the rest with big moves over the course of the past week.
7 years ago
Last Updated: 3 years ago
Halozyme Therapeutics hit a new 52-week low in Monday's session following the release of a business update at JPMorgan’s 34th Annual Healthcare Conference.
7 years ago
Last Updated: 3 years ago
Halozyme Therapeutics has announced a global collaboration and license agreement with AbbVie.
8 years ago
Last Updated: 8 years ago
Many investors are looking for where to put their money now that the Dow Jones Industrial Average has hit 18,000.
8 years ago
Last Updated: 8 years ago
Wednesday's top analyst upgrades, downgrades and initiations from top research calls from around Wall Street include Monsanto and Virgin America.
8 years ago
Last Updated: 8 years ago
Source: ThinkstockInvestors and speculators often flock to the world biotech for emerging drugs of the future. It is no secret at all that the biotech sector is full of all sorts of risks, making and...
9 years ago